Literature DB >> 8531541

Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis.

B B Tan1, D Weald, I Strickland, P S Friedmann.   

Abstract

BACKGROUND: The role of housedust-mite (HDM) allergen (Der p1) in the pathogenesis of atopic dermatitis is controversial. We tested the hypothesis that atopic dermatitis improves if amounts of HDM allergen in the home are reduced.
METHODS: Active treatment comprised Goretex bedcovers (placebo, cotton covers), benzyltannate spray (placebo, water), and a high-filtration vacuum cleaner (placebo, a conventional domestic vacuum cleaner). Dust was sampled monthly from the mattress covers and bedroom and living-room carpets. 48 patients (24 adults [mean age 30] and 24 children [mean age 10]) completed the 6-month study. 28 were in the active treatment group and 20 in the placebo group.
FINDINGS: The weight of dust collected from Goretex-covered mattresses had fallen by 98% at 1 month (from 386 to 9 mg/m2) with no change thereafter. Placebo covers caused a smaller reduction in dust load (361 to 269 mg/m2); the difference between active and placebo covers at 6 months was highly significant (p = 0.002). Both active and placebo treatments caused significant reductions in Der p1 concentrations in bedroom and living-room carpets and the differences between the treatments were not significant. The severity of eczema decreased in both groups, but the active group showed significantly greater improvements in severity score (difference between mean final scores 4.3 units, p = 0.006) and area affected (difference between mean final areas 10%, p = 0.006) in analysis of covariance with initial mattress dust weights and bedroom carpet Der p1 load as covariates. Reported analysis with final values for the covariates showed that most of the treatment effect was due to the reduction in mattress dust and carpet Der p1.
INTERPRETATION: The activity of atopic dermatitis can be greatly reduced by effective HDM avoidance. Methods to identify individuals who will benefit most from such measures are needed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8531541     DOI: 10.1016/s0140-6736(96)91556-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

Review 1.  Clinical evidence: atopic eczema.

Authors:  C Charman
Journal:  BMJ       Date:  1999-06-12

Review 2.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  The role of patch testing for chemical and protein allergens in atopic dermatitis.

Authors:  S T Nedorost; K D Cooper
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

Review 4.  Clinical effects of allergen avoidance.

Authors:  A Custovic; A Woodcock
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

Review 5.  New approaches to environmental control.

Authors:  J W Vaughan; T A Platts-Mills
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

6.  Allergen-specific CD8(+) T cells and atopic disease.

Authors:  Suranjith L Seneviratne; Louise Jones; Abigail S King; Antony Black; Sheila Powell; Andrew J McMichael; Graham S Ogg
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 7.  Childhood atopic eczema.

Authors:  Ross St C Barnetson; Maureen Rogers
Journal:  BMJ       Date:  2002-06-08

8.  The role of airborne proteins in atopic dermatitis.

Authors:  Sarah Grim Hostetler; Benjamin Kaffenberger; Todd Hostetler; Matthew J Zirwas
Journal:  J Clin Aesthet Dermatol       Date:  2010-01

Review 9.  Dust mite allergen avoidance as a preventive and therapeutic strategy.

Authors:  Aida Semic Jusufagic; Angela Simpson; Ashley Woodcock
Journal:  Curr Allergy Asthma Rep       Date:  2006-11       Impact factor: 4.806

Review 10.  [Atopic patch test. Atopic eczema and allergy].

Authors:  U Darsow; J Ring
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.